vs
Orthofix Medical Inc.（OFIX）与威瑞信（VRSN）财务数据对比。点击上方公司名可切换其他公司
威瑞信的季度营收约是Orthofix Medical Inc.的1.9倍（$425.3M vs $219.9M），威瑞信净利率更高（48.5% vs -1.0%，领先49.5%），威瑞信同比增速更快（7.6% vs 2.0%），威瑞信自由现金流更多（$285.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 5.2%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
威瑞信是总部位于美国弗吉尼亚州雷斯顿的网络基础设施服务商，运营全球互联网13台根域名服务器中的2台，同时是.com、.net、.name、.cc等顶级域名的权威注册管理机构，还负责.jobs、.edu等赞助类顶级域名的后端系统运维工作。
OFIX vs VRSN — 直观对比
营收规模更大
VRSN
是对方的1.9倍
$219.9M
营收增速更快
VRSN
高出5.6%
2.0%
净利率更高
VRSN
高出49.5%
-1.0%
自由现金流更多
VRSN
多$268.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $425.3M |
| 净利润 | $-2.2M | $206.2M |
| 毛利率 | 71.1% | 88.5% |
| 营业利润率 | 0.2% | 67.0% |
| 净利率 | -1.0% | 48.5% |
| 营收同比 | 2.0% | 7.6% |
| 净利润同比 | 92.4% | 7.7% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXVRSN
| Q4 25 | $219.9M | $425.3M | ||
| Q3 25 | $205.6M | $419.1M | ||
| Q2 25 | $203.1M | $409.9M | ||
| Q1 25 | $193.6M | $402.3M | ||
| Q4 24 | $215.7M | $395.4M | ||
| Q3 24 | $196.6M | $390.6M | ||
| Q2 24 | $198.6M | $387.1M | ||
| Q1 24 | $188.6M | $384.3M |
净利润OFIXVRSN
| Q4 25 | $-2.2M | $206.2M | ||
| Q3 25 | $-22.8M | $212.8M | ||
| Q2 25 | $-14.1M | $207.4M | ||
| Q1 25 | $-53.1M | $199.3M | ||
| Q4 24 | $-29.1M | $191.5M | ||
| Q3 24 | $-27.4M | $201.3M | ||
| Q2 24 | $-33.4M | $198.8M | ||
| Q1 24 | $-36.0M | $194.1M |
毛利率OFIXVRSN
| Q4 25 | 71.1% | 88.5% | ||
| Q3 25 | 72.2% | 88.4% | ||
| Q2 25 | 68.7% | 88.0% | ||
| Q1 25 | 62.8% | 87.7% | ||
| Q4 24 | 69.0% | 87.8% | ||
| Q3 24 | 68.7% | 88.0% | ||
| Q2 24 | 67.8% | 87.8% | ||
| Q1 24 | 67.5% | 87.2% |
营业利润率OFIXVRSN
| Q4 25 | 0.2% | 67.0% | ||
| Q3 25 | -8.3% | 67.8% | ||
| Q2 25 | -7.9% | 68.5% | ||
| Q1 25 | -25.2% | 67.4% | ||
| Q4 24 | -5.3% | 66.7% | ||
| Q3 24 | -9.6% | 68.9% | ||
| Q2 24 | -12.5% | 68.8% | ||
| Q1 24 | -15.6% | 67.4% |
净利率OFIXVRSN
| Q4 25 | -1.0% | 48.5% | ||
| Q3 25 | -11.1% | 50.8% | ||
| Q2 25 | -6.9% | 50.6% | ||
| Q1 25 | -27.4% | 49.5% | ||
| Q4 24 | -13.5% | 48.4% | ||
| Q3 24 | -13.9% | 51.5% | ||
| Q2 24 | -16.8% | 51.4% | ||
| Q1 24 | -19.1% | 50.5% |
每股收益（稀释后）OFIXVRSN
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $580.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $-2.2B |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXVRSN
| Q4 25 | $82.0M | $580.5M | ||
| Q3 25 | $62.9M | $617.7M | ||
| Q2 25 | $65.6M | $593.8M | ||
| Q1 25 | $58.0M | $648.5M | ||
| Q4 24 | $83.2M | $599.9M | ||
| Q3 24 | $30.1M | $644.9M | ||
| Q2 24 | $26.4M | $689.9M | ||
| Q1 24 | $27.0M | $924.7M |
总债务OFIXVRSN
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXVRSN
| Q4 25 | $450.0M | $-2.2B | ||
| Q3 25 | $442.5M | $-2.1B | ||
| Q2 25 | $458.3M | $-2.0B | ||
| Q1 25 | $458.3M | $-2.0B | ||
| Q4 24 | $503.1M | $-2.0B | ||
| Q3 24 | $525.9M | $-1.9B | ||
| Q2 24 | $546.0M | $-1.8B | ||
| Q1 24 | $570.3M | $-1.6B |
总资产OFIXVRSN
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.4B | ||
| Q2 25 | $837.2M | $1.4B | ||
| Q1 25 | $823.1M | $1.4B | ||
| Q4 24 | $893.3M | $1.4B | ||
| Q3 24 | $867.9M | $1.5B | ||
| Q2 24 | $882.0M | $1.5B | ||
| Q1 24 | $906.0M | $1.7B |
负债/权益比OFIXVRSN
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $289.6M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $285.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 67.0% |
| 资本支出强度资本支出/营收 | 4.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 1.40× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $1.1B |
8季度趋势，按日历期对齐
经营现金流OFIXVRSN
| Q4 25 | $27.7M | $289.6M | ||
| Q3 25 | $12.4M | $307.7M | ||
| Q2 25 | $11.6M | $202.5M | ||
| Q1 25 | $-18.4M | $291.3M | ||
| Q4 24 | $23.7M | $231.5M | ||
| Q3 24 | $11.7M | $253.4M | ||
| Q2 24 | $9.0M | $160.4M | ||
| Q1 24 | $-18.6M | $257.3M |
自由现金流OFIXVRSN
| Q4 25 | $16.8M | $285.1M | ||
| Q3 25 | $2.5M | $303.0M | ||
| Q2 25 | $4.5M | $194.7M | ||
| Q1 25 | $-25.1M | $285.5M | ||
| Q4 24 | $15.2M | $222.0M | ||
| Q3 24 | $6.3M | $247.8M | ||
| Q2 24 | $-360.0K | $151.2M | ||
| Q1 24 | $-29.1M | $253.5M |
自由现金流率OFIXVRSN
| Q4 25 | 7.6% | 67.0% | ||
| Q3 25 | 1.2% | 72.3% | ||
| Q2 25 | 2.2% | 47.5% | ||
| Q1 25 | -13.0% | 71.0% | ||
| Q4 24 | 7.0% | 56.1% | ||
| Q3 24 | 3.2% | 63.4% | ||
| Q2 24 | -0.2% | 39.1% | ||
| Q1 24 | -15.4% | 66.0% |
资本支出强度OFIXVRSN
| Q4 25 | 4.9% | 1.1% | ||
| Q3 25 | 4.8% | 1.1% | ||
| Q2 25 | 3.5% | 1.9% | ||
| Q1 25 | 3.5% | 1.4% | ||
| Q4 24 | 4.0% | 2.4% | ||
| Q3 24 | 2.7% | 1.4% | ||
| Q2 24 | 4.7% | 2.4% | ||
| Q1 24 | 5.6% | 1.0% |
现金转化率OFIXVRSN
| Q4 25 | — | 1.40× | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | — | 1.21× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 1.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
VRSN
暂无分部数据
